• Dual Incretin Agonist – Tirzepatide is a first-in-class peptide that activates both GLP-1 and GIP receptors, enhancing insulin secretion while reducing glucagon release.

• Diabetes Research – Extensively studied for improving glycemic control in type 2 diabetes models.

• Weight Management – Research indicates strong effects on appetite suppression, reduced caloric intake, and significant weight loss.

• Metabolic Health – Investigated for improving insulin sensitivity, lipid metabolism, and markers of metabolic syndrome.

• Cardiovascular Support – Preclinical data suggest potential benefits in reducing inflammation and cardiovascular risk factors.

• Extended Half-Life – Engineered for once-weekly administration in clinical studies due to its long plasma half-life.

For research use only (RUO). By purchasing this product, you agree to comply with all stated Terms & Conditions. Store reconstituted solution refrigerated at 2–8 °C .